Advertisement

Topics

"TTM-based Intervention And MI In CHD Patients∨derfield=date∨derval=DESC" News Stories

16:22 EDT 16th July 2019 | BioPortfolio

Here are the most relevant search results for "TTM-based Intervention And MI In CHD Patients∨derfield=date∨derval=DESC" found in our extensive news archives from over 250 global news sources.

More Information about TTM-based Intervention And MI In CHD Patients∨derfield=date∨derval=DESC on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about TTM-based Intervention And MI In CHD Patients∨derfield=date∨derval=DESC for you to read. Along with our medical data and news we also list TTM-based Intervention And MI In CHD Patients∨derfield=date∨derval=DESC Clinical Trials, which are updated daily. BioPortfolio also has a large database of TTM-based Intervention And MI In CHD Patients∨derfield=date∨derval=DESC Companies for you to search.

Showing "based Intervention Patients derfield date derval DESC" News Articles 1–25 of 40,000+

Tuesday 16th July 2019

Washington is considering proposals to have the government set drug prices in the US based on a process known as international reference pricing. Get the facts on why this misguided idea would mean less access for patients to the medicines they rely on ht

Washington is considering proposals to have the government set drug prices in the US based on a process known as international reference pricing. Get the facts on why this misguided idea would mean less access for patients to the medicines they rely on https://catalyst.phrma.org/setting-the-record-straight-on-international-reference-pricing …


NextGen Healthcare Partners with Appriss Health to Combat Substance Use Disorder

Enhanced prescription capabilities in NextGen Office will help prevent the illegal acquisition of controlled substances from multiple sources NextGen Healthcare, Inc. (NASDAQ:NXGN), the leading provider of ambulatory-focused technology solutions, announced today that it has integrated

Charles River Laboratories Schedules Second-Quarter 2019 Earnings Release and Conference Call

Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2019 financial results on Wednesday, July 31st, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, July 31st, at 8:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of t...


Henry Schein Enters the Italian Dental Practice Management Software Market With Acquisition of Elite Computer Italia

Acquisition Expands Henry Schein One’s International Presence and Establishes Leading Software Position in Italy under the OrisLine Brand Henry Schein, Inc. (Nasdaq: HSIC) today announced that Henry Schein One has acquired Elite Computer Italia S.r.L. (Elite), a full-service software company that delivers state-of-the-art practice management solutions to dental practices and dental laboratorie...

Senseonics Announces Public Offering of Common Stock

Senseonics Holdings, Inc. (“Senseonics”) (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that it has commenced a registered underwritten public offering of $25.0 million of its shares of common stock. In addition, Senseonics anti...

Senseonics Announces Commencement of Convertible Notes Offering

Senseonics Holdings, Inc. (“Senseonics” or the “Company”) (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the commencement of an offering of $80.0 million aggregate principal amount of 5.25% convertible senior notes due 2025 ...

Gilead Sciences to Release Second Quarter 2019 Financial Results on Tuesday, July 30, 2019

-- Conference Call and Webcast to Follow -- Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2019 financial results will be released on Tuesday, July 30, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the second quarter 2019 and provide a business update. The live...

Senseonics Holdings, Inc. Reports Preliminary Second Quarter 2019 Net Revenue

Preliminary second quarter net revenue between $4.4M and $4.7M Nearly 4,500 Eversense® System prescriptions written in the U.S. as of June 30, 2019 Expanded commercial coverage to 76M lives as of June 30, 2019 Senseonics Holdings, Inc. (“Senseonics” or “Company”) (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, im...

Seattle Genetics Reports Second Quarter 2019 Financial Results

-Record ADCETRIS® (Brentuximab Vedotin) Net Sales in U.S. and Canada of $159.0 Million in the Second Quarter, an Increase of 30 Percent Over the Second Quarter of 2018- -Biologics License Application Submitted to FDA for Enfortumab Vedotin to Treat Advanced or Metastatic Urothelial Cancer Based on Results from the EV-201 Pivotal Trial- -Topline Results from Tucatinib HER2CLIMB Pivotal Trial ...

AVROBIO Announces Proposed Public Offering of Common Stock

AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced that it intends to offer and sell, subject to market and other conditions, $100.0 million of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 30-day option to purchase up to $15.0 million of additional shares of its common stock (15%)...

Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-ANG3

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ARO-ANG3 for the treatment of homozygous familial hypercholesterolemia (HoFH). ARO-ANG3 is a subcutaneously administered RNA interference (RNAi)-based investigational medicine targeting angiopoietin like protein 3 (ANGPTL3) being developed for the...

Global FoodGrade Industrial Gasses Market Research Report 20122024 [Report Updated: 25052019] Prices from USD $2040

SummaryThe global FoodGrade Industrial Gasses market will reach xxx Million USD in 2019 with CAGR xx% 20192024. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to describe the content about the factors influencing market dynamics, policy, economic, technology and market entry etc.Based on products type, the report des...

Alzamend Neuro™ Announces Appointment of Dr. Eric McDade to Its Scientific Advisory Board

Company Selects Innovative Researcher and Leader, Associate Director of DIAN-TU Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it had appointed Eric McDade, DO, a board-certified cognitive neurologist, as its next member to its Scientific Advisory Board. Dr. McDade, an innovative researcher and leader since 2010, has focused his activities on the evaluation of th...

Valley Presbyterian Hospital Receives Get With The Guidelines-Stroke Bronze Quality Achievement Award

American Heart Association Award recognizes Valley Presbyterian Hospital’s commitment to quality stroke care Valley Presbyterian Hospital has received the American Heart Association/American Stroke Association’s Get With The Guidelines®-Stroke Bronze Quality Achievement Award. The award recognizes the hospital’s commitment to ensuring stroke patients receive the most appropriate treatment...

Neutron Therapeutics to Install Its BNCT Cancer Therapy System into Japan’s Largest Private Hospital Chain

Neutron Therapeutics, Inc (NTI) has agreed with Tokushukai Medical Group (TMG) to install a nuBeam system for Boron-Neutron Capture Therapy (BNCT) at Shonan Kamakura General Hospital (SKGH) in Kanagawa Prefecture, Japan. Developed by NTI and having roots in technology originating at MIT, nuBeam is the world’s most powerful accelerator-based neutron source designed specifically to deliver this cu...

BrightQuest Treatment Centers Earns Gold Seal of Approval® From The Joint Commission

BrightQuest San Diego Honored With Prestigious Behavioral Health Care Accreditation BrightQuest San Diego, a long-term treatment center for individuals suffering from complex mental illness, has earned The Joint Commission’s Gold Seal of Approval for behavioral health care accreditation by demonstrating compliance with its performance standards. The Gold Seal of Approval® is a symbol of quali...

Debate Continues Between Upfront Surgery and Neoadjuvant Chemo in Advanced Ovarian Cancer

R. Wendel Naumann, MD, discusses the criteria for primary debulking versus neoadjuvant chemotherapy in patients with advanced ovarian cancer.

The largest study to date of a “cancer vaccine” plus one of the immunotherapy drugs that has revolutionized cancer treatment found that they kept patients’ tumors in check longer, on average, than drugs alone. https://buff.ly/2lx02DU 

The largest study to date of a “cancer vaccine” plus one of the immunotherapy drugs that has revolutionized cancer treatment found that they kept patients’ tumors in check longer, on average, than drugs alone. https://buff.ly/2lx02DU 

For most #lungcancer patients, symptoms are easily overlooked – until the disease has reached an advanced stage. Share these common signs and symptoms to help support earlier diagnosis and treatment for patients. #LCSMpic.twitter.com/xjuqC7PNwE

For most #lungcancer patients, symptoms are easily overlooked – until the disease has reached an advanced stage. Share these common signs and symptoms to help support earlier diagnosis and treatment for patients. #LCSM pic.twitter.com/xjuqC7PNwE

Shining stars: Luminaries in the generics industry

New Data Change Management of Frontline Metastatic Renal Cell Carcinoma

Recently, new data were presented for patients in different risk categories that significantly changed the surgical and medical management of patients with newly diagnosed metastatic renal cell carcinoma. 

Wolters Kluwer's ELM Solutions Builds Pharmacy Building for Charitable Organization Sevalaya in India

Wolters Kluwer’s ELM Solutions today announced it has partnered with Sevalaya to build a Pharmacy building in Kasuva, India. The Pharmacy building, located about 40 km from Chennai city, is part of ELM Solutions’ ongoing commitment to positively impact local communities where the firm has a presence

EOS imaging Reports Half-Year 2019 Revenues

Upturn in commercial performance in the second quarter Regulatory News: EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI) a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical planning today announces preliminary consolidated revenues for the half year ending June 30, 2019. SECOND QUARTER & FIRST SEMESTER 2019 HIGHLIGHTS ...

OncLive® Presents State of the Science Summit™ on Multiple Myeloma

OncLive®, the nation’s leading multimedia resource focused on providing oncology professionals with the most current and insightful information they need to offer the best patient care, will host its latest State of the Science Summit™ on multiple myeloma on Thursday, July 18, from 5 to 9 p.m. at New York Marriott East Side in New York, New York. The summit will be co-chaired by Ajai Chari, ...

PPD expands patient access to clinical trials via collaboration with cancer center

PPDâs patient enrollment business expands access to cancer patients treated in the community setting as part of a new collaboration with a hospital and outpatient center network.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks